Total Payments
$1,580
2024 Payments
$130.50
Companies
12
Transactions
14
Medicare Patients
20,501
Medicare Billing
$8.0M
Payment Breakdown by Category
Other$1,000 (63.3%)
Food & Beverage$433.30 (27.4%)
Education$146.34 (9.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,000 | 2 | 63.3% |
| Food and Beverage | $433.30 | 8 | 27.4% |
| Education | $146.34 | 4 | 9.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $500.00 | 1 | $0 (2019) |
| Takeda Pharmaceuticals U.S.A., Inc. | $500.00 | 1 | $0 (2019) |
| Tactile Systems Technology Inc | $147.23 | 2 | $0 (2024) |
| Seattle Genetics, Inc. | $114.82 | 2 | $0 (2019) |
| AngioDynamics, Inc. | $114.03 | 1 | $0 (2019) |
| Lilly USA, LLC | $100.87 | 1 | $0 (2023) |
| PUMA BIOTECHNOLOGY, INC. | $23.27 | 1 | $0 (2022) |
| Daiichi Sankyo Inc. | $21.26 | 1 | $0 (2022) |
| ABBVIE INC. | $19.54 | 1 | $0 (2023) |
| Seagen Inc. | $15.54 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $130.50 | 1 | Tactile Systems Technology Inc ($130.50) |
| 2023 | $135.95 | 3 | Lilly USA, LLC ($100.87) |
| 2022 | $61.26 | 3 | PUMA BIOTECHNOLOGY, INC. ($23.27) |
| 2021 | $11.92 | 1 | Gilead Sciences, Inc. ($11.92) |
| 2020 | $11.16 | 1 | E.R. Squibb & Sons, L.L.C. ($11.16) |
| 2019 | $1,217 | 4 | Incyte Corporation ($500.00) |
| 2018 | $12.29 | 1 | Seattle Genetics, Inc. ($12.29) |
All Payment Transactions
14 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/02/2024 | Tactile Systems Technology Inc | Flexitouch Plus (Device), Entre Plus | Food and Beverage | In-kind items and services | $130.50 | General |
| Category: PNEUMATIC COMPRESSOR | ||||||
| 05/25/2023 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $19.54 | General |
| Category: ONCOLOGY | ||||||
| 05/25/2023 | Seagen Inc. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $15.54 | General |
| Category: Oncology | ||||||
| 03/09/2023 | Lilly USA, LLC | VERZENIO (Drug) | Education | In-kind items and services | $100.87 | General |
| Category: Oncology | ||||||
| 11/10/2022 | Tactile Systems Technology Inc | Flexitouch Plus (Device), entre | Food and Beverage | In-kind items and services | $16.73 | General |
| Category: PNEUMATIC COMPRESSOR | ||||||
| 07/12/2022 | Daiichi Sankyo Inc. | ENHERTU (Drug) | Education | In-kind items and services | $21.26 | General |
| Category: ONCOLOGY | ||||||
| 05/04/2022 | PUMA BIOTECHNOLOGY, INC. | NERLYNX (Drug) | Food and Beverage | In-kind items and services | $23.27 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 02/11/2020 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $11.16 | General |
| Category: Cardiovascular | ||||||
| 09/26/2019 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $102.53 | General |
| Category: Oncology | ||||||
| 07/18/2019 | AngioDynamics, Inc. | — | Food and Beverage | In-kind items and services | $114.03 | General |
| Category: VIT | ||||||
| 03/14/2019 | Takeda Pharmaceuticals U.S.A., Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $500.00 | General |
| 02/21/2019 | Incyte Corporation | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $500.00 | General |
| 04/11/2018 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Education | In-kind items and services | $12.29 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 70 | 5,224 | 118,247 | $8.4M | $1.7M |
| 2022 | 75 | 5,469 | 149,633 | $11.1M | $2.4M |
| 2021 | 71 | 4,960 | 145,711 | $9.5M | $2.2M |
| 2020 | 73 | 4,848 | 158,455 | $7.7M | $1.8M |
Total Patients
20,501
Total Services
572,046
Medicare Billing
$8.0M
Procedure Codes
289
All Medicare Procedures & Services
289 procedure records from CMS Medicare Utilization — Page 1 of 12
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 29 | 20,600 | $3.0M | $886,787 | 29.4% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 11 | 5,760 | $783,720 | $218,524 | 27.9% |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 15 | 3,084 | $772,708 | $102,948 | 13.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 404 | 793 | $213,571 | $70,356 | 32.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 174 | 324 | $117,706 | $43,480 | 36.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 137 | 424 | $353,815 | $42,721 | 12.1% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 24 | 17,155 | $360,255 | $40,249 | 11.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 345 | 464 | $84,146 | $28,457 | 33.8% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 33 | 31,500 | $157,500 | $27,662 | 17.6% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 12 | 240 | $346,560 | $20,420 | 5.9% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 20 | 129 | $508,002 | $17,063 | 3.4% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 40 | 11,830 | $106,470 | $16,238 | 15.3% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 44 | 221 | $15,470 | $15,749 | 101.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 509 | 2,034 | $71,190 | $15,456 | 21.7% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 468 | 1,477 | $91,574 | $15,287 | 16.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 106 | 216 | $65,664 | $9,780 | 14.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 441 | 1,026 | $19,494 | $8,603 | 44.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 51 | 76 | $23,135 | $7,025 | 30.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 61 | 61 | $29,328 | $6,840 | 23.3% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 118 | 576 | $60,480 | $6,645 | 11.0% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 43 | 101 | $41,119 | $5,088 | 12.4% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 25 | 85 | $21,179 | $4,557 | 21.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 27 | 27 | $16,282 | $4,393 | 27.0% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 169 | 322 | $18,676 | $4,278 | 22.9% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 83 | 149 | $22,648 | $3,297 | 14.6% |
About Dr. Padmaja Mallidi, M.D
Dr. Padmaja Mallidi, M.D is a Hematology & Oncology healthcare provider based in Roanoke, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1629044821.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Padmaja Mallidi, M.D has received a total of $1,580 in payments from pharmaceutical and medical device companies, with $130.50 received in 2024. These payments were reported across 14 transactions from 12 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1,000).
As a Medicare-enrolled provider, Mallidi has provided services to 20,501 Medicare beneficiaries, totaling 572,046 services with total Medicare billing of $8.0M. Data is available for 4 years (2020–2023), covering 289 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Roanoke, VA
- Active Since 02/27/2006
- Last Updated 11/02/2007
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1629044821
Products in Payments
- Flexitouch Plus (Device) $147.23
- ADCETRIS (Biological) $114.82
- VERZENIO (Drug) $100.87
- NERLYNX (Drug) $23.27
- ENHERTU (Drug) $21.26
- VENCLEXTA (Drug) $19.54
- TUKYSA (Drug) $15.54
- ELIQUIS (Drug) $11.16
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Roanoke
Amanda Gillespie-Twardy, M.d, M.D
Hematology & Oncology — Payments: $15,362
Hematology & Oncology $15,362
Mark Kochenderfer, Md, MD
Hematology & Oncology — Payments: $12,819
Hematology & Oncology $12,819
Dr. Harry Mccoy, M.d, M.D
Hematology & Oncology — Payments: $544.52
Hematology & Oncology $544.52
Mrs. Kirsten Hinson, Fnp-C, FNP-C
Hematology & Oncology — Payments: $421.40
Hematology & Oncology $421.40
Joshua Morales, Md, MD
Hematology & Oncology — Payments: $412.41
Hematology & Oncology $412.41
Dr. William Fintel, M.d, M.D
Hematology & Oncology — Payments: $388.95
Hematology & Oncology $388.95